Global programmatic use of bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis

Hdl Handle:
http://hdl.handle.net/10144/619095
Title:
Global programmatic use of bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis
Authors:
Cox, V; Brigden, G; Crespo, RH; Lessem, E; Lynch, S; Rich, ML; Waning, B; Furin, J
Journal:
The International Journal of Tuberculosis and Lung Disease
Abstract:
The World Health Organization recommended two new drugs, bedaquiline (BDQ) and delamanid (DLM), for the treatment of multidrug-resistant tuberculosis (MDR-TB) in 2013 and 2014, respectively. An estimated one third of patients with MDR-TB would benefit from the inclusion of these drugs in their treatment regimens.
Publisher:
International Union Against Tuberculosis and Lung Disease
Issue Date:
1-Apr-2018
URI:
http://hdl.handle.net/10144/619095
DOI:
10.5588/ijtld.17.0706
PubMed ID:
29562988
Submitted date:
2018-04-17
Language:
en
ISSN:
1815-7920
Appears in Collections:
TB

Full metadata record

DC FieldValue Language
dc.contributor.authorCox, Ven
dc.contributor.authorBrigden, Gen
dc.contributor.authorCrespo, RHen
dc.contributor.authorLessem, Een
dc.contributor.authorLynch, Sen
dc.contributor.authorRich, MLen
dc.contributor.authorWaning, Ben
dc.contributor.authorFurin, Jen
dc.date.accessioned2018-04-17T16:40:38Z-
dc.date.available2018-04-17T16:40:38Z-
dc.date.issued2018-04-01-
dc.date.submitted2018-04-17-
dc.identifier.citationGlobal programmatic use of bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis. 2018, 22 (4):407-412 Int. J. Tuberc. Lung Dis.en
dc.identifier.issn1815-7920-
dc.identifier.pmid29562988-
dc.identifier.doi10.5588/ijtld.17.0706-
dc.identifier.urihttp://hdl.handle.net/10144/619095-
dc.description.abstractThe World Health Organization recommended two new drugs, bedaquiline (BDQ) and delamanid (DLM), for the treatment of multidrug-resistant tuberculosis (MDR-TB) in 2013 and 2014, respectively. An estimated one third of patients with MDR-TB would benefit from the inclusion of these drugs in their treatment regimens.en
dc.language.isoenen
dc.publisherInternational Union Against Tuberculosis and Lung Diseaseen
dc.rightsArchived with thanks to The International Journal of Tuberculosis and Lung Disease : the official journal of the International Union against Tuberculosis and Lung Diseaseen
dc.titleGlobal programmatic use of bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosisen
dc.identifier.journalThe International Journal of Tuberculosis and Lung Diseaseen

Related articles on PubMed

All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.